Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erin Larkins

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung CancerOladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
The Oncologist|February 14, 2018
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> MutationsLauretta Odogwu, Luckson Mathieu, Gideon Blumenthal, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
The Oncologist|March 9, 2021
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung CancerLuckson Mathieu, Sujay Shah, Lee Pai-Scherf, et al.
The Oncologist|December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M MutationLauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following CrizotinibErin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Cancer Research Communications|March 2, 2023
Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial DataQi Liu, Chenan Zhang, Yue Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural MesotheliomaErica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsKatie Chon, Erin Larkins, Somak Chatterjee, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung CancerOladimeji Akinboro, Nicole Drezner, Anup Amatya, et al.
The Oncologist|February 14, 2018
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> MutationsLauretta Odogwu, Luckson Mathieu, Gideon Blumenthal, et al.
Journal of Neuro-Oncology|June 22, 2021
US Food and Drug Administration regulatory updates in neuro-oncologyGautam U Mehta, Amy K Barone, Diana Bradford, et al.
The Oncologist|March 9, 2021
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung CancerLuckson Mathieu, Sujay Shah, Lee Pai-Scherf, et al.
The Oncologist|December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M MutationLauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following CrizotinibErin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Cancer Research Communications|March 2, 2023
Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial DataQi Liu, Chenan Zhang, Yue Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural MesotheliomaErica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsKatie Chon, Erin Larkins, Somak Chatterjee, et al.
Pageof 3